Clinical Investigation

Kidney International (1995) 47, 225–230; doi:10.1038/ki.1995.27

Treatment of hepatitis B virus-associated membranous nephropathy with recombinant alpha-interferon

Ching-Yuang Lin1

1Department of Pediatrics, Veterans General Hospital-Taipei, Taiwan, Republic of China

Correspondence: Ching-Yuang Lin MD PhD, Department of Pediatrics, Veterans General Hospital-Taipei, Shih-Pai, Taipei, Taiwan, 11217, Republic of China.

Received 30 September 1993; Revised 14 July 1994; Accepted 18 July 1994.

Top

Abstract

Treatment of hepatitis B virus-associated membranous nephropathy with recombinant alpha-interferon. An open, randomized trial study on the therapeutic effect of recombinant alpha-interferon (IFNalpha) in 40 patients with hepatitis B virus membranous nephropathy (HBVMN) was conducted. All were pathologically proven to have HBVMN which showed no response to corticosteroid treatment represented by persistent heavy proteinuria. Both HBeAg and HBsAg were positive in all. Group 1 was composed of 20 patients who were treated with recombinant IFNalpha (5 subjects, body wt < 20 kg; 8 subjects, body weight greater than or equal to 20 kg) by subcutaneous (s.c.) injection three times a week for 12 months. In group 2 there were 20 patients who received supportive treatment only. At the end of the third month of treatment, all patients in Group 1 were free of proteinuria. In contrast, 10 patients (50%) in Group 2 had persistent heavy proteinuria and another 10 patients (50%) had light proteinuria with exacerbation during respiratory tract infection. At the end of the twelfth month, 8 patients (40%) in Group 2 still had persistent heavy proteinuria and 12 patients (60%) had light proteinuria with frequent relapses. Eight patients (40%) in Group 1 had HBeAg seroconversion between the fourth and sixth months and HBsAg seroconversion between the tenth and twelfth months. HBe seroconversion only [HBeAg (-)/HBsAg (+)] was found in four patients. Four patients had no change in HBV serological markers [HBeAg (+)/HBsAg (+)]. The remaining 4 patients had HBeAg (-)/ HBeAb (+) HBsAg (-)/HBsAb (-) at the end of the twelfth month. In contrast, there was no seroconversion of HBeAg (+)/HBsAg (+) in Group 2 patients. Flu-like symptoms were found in all patients during the first two weeks of IFNalpha treatment and disappeared spontaneously. Psychiatric problems were late side-effects found in 30% of patients which disappeared when the dosage of IFN was reduced. These results suggest that IFNalpha therapy is of value in complete resolution of heavy proteinuria, and provides some benefit in seroconversion of HBeAg (+)/HBsAg (+) in children with HBVMN.

Top

References

  1. Beasley RP, Hwang LY, Lin CC, Chien CS: Hepatocellular carcinoma and HBV: A prospective study of 22,707 men in Taiwan. Lancet 2:1129–1132, 1981 | Article | PubMed | ISI | ChemPort |
  2. Beasley RP: Hepatitis B virus as the etiologic agent in hepatocellular carcinoma—epidemiologic considerations. Hepatology 2:21S–26S, 1982
  3. Nayak NC, Dhark A, Sachdeva R, Mittal A, Seth HN, Sndarsanam D, Raddy B, Wagholikar UL, Reddy CRM: Association of human hepatocellular carcinoma and cirrhosis with hepatitis B virus surface and core antigens in the liver. Int J Cancer 20:643–654, 1977
  4. Combes B, Stastny P, Shorey J, Engenbrodt EH, Barrera A, Hull AR, Carter NW: Glomerulonephritis with deposition of Australia antigen-antibody complexes in glomerular basement membrane. Lancet 2:234–236, 1971 | PubMed | ISI | ChemPort |
  5. Lin CY: Hepatitis B virus associated membranous nephrophaty: Clinical features, immunologic profiles and outcomes. Nephron 55:37–44, 1990
  6. Lin CY, Lo S: Treatment of hepatitis B virus-associated membranous nephropathy with adenine arabinoside and thymic extract. Kidney Int 39:301–306, 1991
  7. Lin CY: Clinical features and natural course of HBV-related glomerulopathy in children. Kidney Int 40:S46–S53, 1991 | ISI |
  8. Lin CY: Hepatitis B virus deoxyribonucleic acid in kidney cells probably leading to viral pathogenesis among hepatitis B virus associated membranous nephropathy patients. Nephron 63:58–64, 1993
  9. Rodney DG, Wiggelinkhuizen J: The clinical course of hepatitis B virus-associated nephropathy. Pediatr Nephrol 8:11–14, 1994
  10. Kleinknecht C, Levy M, Peix A, Broyer M, Courtecuisse V: Membranous glomerulonephritis and hepatitis B surface antigenaemia in children. J Pediatr 95:946–952, 1979 | PubMed | ISI | ChemPort |
  11. Elidressey ATH, Abdurrahman MB, Raima S, Lynch JB: Hepatitis B surface antigen associated nephrotic syndrome. Ann Trop Paediatr 8:157–161, 1988
  12. Porres JC, Carreno V, Ruiz M, Marron JA, Bartolome J: Interferon antibodies in patients with chronic HBV infection treated with recombinant interferon. J Hepatol 8:351–357, 1989
  13. Mizushima N, Kanai K, Matsuda H, Matsumoto M, Tamakoshi K, Ishii H, Nakajima T, Yoshima T, Kimura M, Nagase M: Improvement of proteinuria in a case of hepatitis B-associated glomerulonephritis after treatment with interferon. Gastroenterology 92:524–526, 1987 | PubMed | ChemPort |
  14. Lin CY: Hepatitis B virus associated nephropathy in children. Satellite symposium of virus related renal disease, in XIth International Congress of Nephrology, July 22–24, 1990, abstract P.25, and oral presentation
  15. Lisker-Melman M, Webb D, Di Bisceglie AM, Kassianides C, Martin P, Rustgi V, Waggoner JG, Park Y, Hoofnagle JH: Glomerulonephritis caused by chronic hepatitis B virus infection: Treatment with recombinant human alpha-interferon. Ann Intern Med 111:479–483, 1989 | PubMed | ChemPort |
  16. De Man RA, Schalm SW, Van Der Heijden AJ, Ten Kate FWJ, Wolff ED, Heijtink RA: Improvement of hepatitis B-associated glomerulonephritis after antiviral combination therapy. J Hepatol 8:367–372, 1989
  17. Lai KN, Li PKT, Lui SF, Au TC, Tam JSL, Tong KL, Lai FM: Membranous nephropathy related to hepatitis B virus in adults. N Engl J Med 324:1457–1463, 1991 | PubMed | ISI | ChemPort |
  18. Wong SN, Yu ECL, Lok ASF, Chan KW, Lau YL: Interferon treatment for hepatitis B-associated membranous glomerulonephritis in two chinese children. Pediatr Nephrol 6:417–420, 1992
  19. Taniguchi T: Regulation of cytokine gene expression. Annu Rev Immunol 6:439–464, 1988 | Article | PubMed | ISI | ChemPort |
  20. Beresini MH, Lempert MJ, Epstein LB: Overlapping polypeptide induction in human fibroblasts in response to treatment with interfer-on-alpha, interferon-gamma, interleukin-alpha and tumor necrosis factor. J Immunol 140:485–493, 1988
  21. Estrov Z, Kurzrock R, Talpaz M: Interferon basic principles and clinical applications (Chap 1), in Structural, Physical and Physiological Properties of Interferon, Austin, R.G. Landes Co. 1993, 4–10
  22. Ehrenbach T, Churg J: Pathology of membranous nephropathy. Pathol Annu 3:145–186, 1968

Extra navigation

.
ADVERTISEMENT